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Bone marrow failure (BMF) syndromes are severe complications of allogeneic hemato-
poietic stem cell transplantation (allo-HSCT). In this paper, we distinguish two different 
entities, the graft failure (GF) and the poor graft function (PGF), and we review the current 
understanding of the interactions between the immune and hematopoietic compart-
ments in these conditions. We first discuss how GF occurs as the result of classical 
alloreactive immune responses mediated by residual host cellular and humoral immunity 
persisting after conditioning and prevented by host and donor regulatory T cells. We next 
summarize the current knowledge about the contribution of inflammatory mediators to 
the development of PGF. In situations of chronic inflammation complicating allo-HSCT, 
such as graft-versus-host disease or infections, PGF seems to be essentially the result of 
a sustained impairment of hematopoietic stem cells (HSC) self-renewal and proliferation 
caused by inflammatory mediators, such as interferon-γ (IFN-γ) and tumor necrosis 
factor-α, and of induction of apoptosis through the Fas/Fas ligand pathway. Interestingly, 
the production of inflammatory molecules leads to a non-MHC restricted, bystander 
inhibition of hematopoiesis, therefore, representing a promising target for immunolog-
ical interventions. Finally, we discuss immune-mediated impairment of bone marrow 
microenvironment as a potential mechanism hampering hematopoietic recovery. Better 
understanding of immunological mechanisms responsible for BMF syndromes after allo-
HSCT may lead to the development of more efficient immunotherapeutic interventions.
Keywords: bone marrow failure, graft failure, poor graft function, HSCT
inTRODUCTiOn
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is standard of care for many 
hematological diseases, and sustained engraftment of donor stem cells represents a fundamental 
prerequisite for a good outcome. Bone marrow failure (BMF) syndromes remain severe complica-
tions of allo-HSCT associated with considerable morbidity and mortality, highlighting the need for 
therapeutic manipulation. In this paper, we review the current understanding of the complex interac-
tions between the immune and hematopoietic compartments in BMF syndromes after allo-HSCT.
Two entities with different clinical and physiopathological features can be distinguished: the graft 
failure (GF) and the poor graft function (PGF). Unfortunately, in a large number of studies, there 
TABLe 1 | Clinical characteristics of graft failure and poor graft function.
initial donor engraftment initial hematologic recovery Cytopenias Relapse Bone marrow Chimerism status
Graft failure Primary No No Yes No Hypocellular Mixed or full recipient
Secondary Yes Yes
Poor graft function Primary Yes No Yes No Hypocellular Full donor
Secondary Yes Yes
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is not a clear distinction between GF and PGF. Other frequent 
limitations of the literature are the lack of separation between 
primary and secondary cases and the heterogeneity of definition 
criteria. Primary GF is characterized by the lack of donor engraft-
ment and is defined as never having achieved absolute neutrophil 
count ≥0.5 ×  109/L lasting for at least three consecutive days 
without evidence of disease relapse (Table  1). Thus, in case of 
myeloablative conditioning, the patient never recovers from the 
neutropenia making second allo-HSCT the only therapeutic 
option; while in case of reduced intensity conditioning (RIC), 
an autologous recovery may occur. Secondary GF refers to the 
loss of a previously functioning graft (1) associated with loss of 
full donor chimerism. Therefore, in both primary and second-
ary GF, chimerism status is either mixed, with the presence of 
recipient cells, or full recipient. GF incidence ranges from 3.8 to 
5.6% (1–3) and varies significantly according to different trans-
plant settings. Factors associated with increased risk for GF are 
HLA-mismatched grafts, RIC regimens (4), bone marrow (BM) 
grafts, low stem cell dose, non-malignant disorders, major ABO 
incompatibility, female donor grafts for male recipients (1–3), 
myeloproliferative disease (5), and disease status at transplanta-
tion (3). In contrast to GF, PGF is characterized by the presence 
of a full donor chimerism status (Table 1) as donor engraftment 
is achieved and sustained (6). Graft function can be poor either 
as a result of incomplete hematological recovery (primary PGF) 
or of a decrease of blood counts after prompt recovery (secondary 
PGF) (7). It is diagnosed in patients with two or three cytopenic 
lineages, hypoplastic/aplastic BM and full donor chimerism 
(Table 1). PGF occurs in 5–27% of patients (7) and it is associ-
ated with several post allo-HSCT conditions, such as infections, 
mostly viral, use of myelotoxic drugs, and graft-versus-host 
disease (GvHD) (8). Of note, GvHD, a common post allo-HSCT 
complication with an overall incidence up to 59% (9), represents 
the major risk factor for developing PGF (10) either in the context 
of the recently identified entity of BM GvHD (11, 12), or more 
usually, without specifically targeting BM. Thus, cytopenias are 
observed in ~40% of GvHD patients (13), while PGF is also seen 
in the absence of GvHD.
iMMUnOLOGiCAL BASiS OF GRAFT 
FAiLURe
Graft failure occurs as the result of a classical alloreactive immune 
response mediated by residual host immunity persisting after 
the conditioning regimen (Figure 1A). Residual host T cells are 
considered the most prominent effector cells mediating rejection 
(14). Importantly, T-cell-mediated graft rejection can occur in 
both HLA-mismatched (15) and HLA-matched (16) settings, in 
the latter case as a result of responses directed against minor his-
tocompatibility antigens (MiHA). The male-specific H-Y antigen 
represents a good example of a target MiHA involved in graft 
rejection (17, 18), increasing the risk of GF in sex mismatched 
transplantations (2, 19). The molecular pathways involved in 
T-cell-mediated graft rejection are still not completely defined 
and are probably multiple and somehow redundant as ablation of 
perforin, FasL, tumor necrosis factor receptor-1 (TNFR-1), and of 
tumor necrosis factor ligands TRAIL, TWEAK, and TL1A fails to 
prevent rejection (20, 21). Conversely, donor cytotoxic T cells are 
well known to mediate a facilitative effect on HSC engraftment 
(22–24) while graft T-cell depletion is associated with increased 
incidence of GF (25–27).
Residual host natural killer (NK) cells can also eliminate 
donor HSC as demonstrated in early studies in animal models 
(28–30). NK-mediated graft rejection, mainly observed in 
MHC-mismatched transplantations, is the result of a “missing-
self recognition,” when the inhibitory receptors expressed on 
donor NK cells, belonging to the Ly49 family in mice and to the 
killer immunoglobulin-like receptors (KIRs) in humans, fail to 
recognize their cognate MHC class I molecule on host cells (31). 
Graft rejection by host NK cells is, at least partially, dependent on 
perforin-mediated cytotoxicity (32, 33). Similar to donor T cells, 
donor NK cells can facilitate HSC engraftment. In mice, adoptive 
transfer of donor NK cells facilitates HSC engraftment (34, 35), at 
least partly by abrogating the resistance of residual host effector 
immune cells to the graft. In humans, a similar effect has been 
observed in the HLA-haploidentical setting as transplantation 
with KIR ligand incompatible cells in the graft-versus-host direc-
tion conferred a significant protection from graft rejection in 
patients with acute myeloid leukemia (36).
The role of antibody-mediated rejection after allo-HSCT is 
much more controversial (37, 38). Recent studies demonstrate that 
the presence of donor-specific HLA antibodies (DSA), resulting 
in most cases from previous transfusion-induced sensitization, is 
associated with GF in HLA-mismatched (39–42) and haploiden-
tical (42, 43) transplantations. Nevertheless, it is not clear whether 
DSA can actually mediate graft rejection or if they are surrogate 
markers for the cellular immunity that causes graft rejection. 
Recently published data suggest that integrated humoral and 
cellular immunity recognizing the same alloantigen of the donor 
can mediate graft rejection in DSA-positive patients undergoing 
HLA-mismatched cord blood allo-HSCT (44). Furthermore, 
patients displaying pretransplant donor-specific antibodies 
directed against CD34+/VEGFR-2+ endothelial progenitor stem 
cells presented a higher risk of GF, providing additional evidence 
supporting antibody-mediated rejection (45).
CD4+CD25+ regulatory T cells (Tregs) are critical immu-
nomodulatory cells participating to immune and hematopoietic 
FiGURe 1 | immunological basis of GF and PGF. Immunological interactions between host (blue) and donors (brown) cells during (A) graft failure and (B) poor 
graft function. Arrows indicate facilitating effects and dashed lines indicate inhibitory effects. CTL, cytotoxic T lymphocyte; APC, antigen-presenting cell; OB, 
osteoblast; BMME, bone marrow microenvironment.
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compartment interactions. In a syngeneic setting, Treg abla-
tion enhanced early post-transplant hematopoiesis while 
 co-administration of Tregs at time of transplantation inhibited 
myelopoiesis (46). Conversely, in the allogeneic setting, an 
engraftment facilitating effect of both host and donor Tregs 
seems to exist. Host Tregs prevent GF as their prior removal using 
anti-CD25 mAbs strongly enhanced allogeneic BM rejection 
in mice (47). Accordingly, adoptive transfer of host-type Tregs 
improved durable engraftment of allogeneic BM grafts (48–50). 
Interestingly, high resolution in  vivo imaging showed marked 
co-localization of HSCs with host Tregs on the endosteal surface 
in the calvarial and trabecular BM, while after Treg depletion 
HSCs were lost, suggesting a direct effect of Tregs in HSC niches 
generation and maintenance (51). This effect seems to be essen-
tially dependent on IL-10 production by Treg as IL-10 blockade 
by monoclonal antibodies or the use of Tregs isolated from IL-10 
KO mice prevent the Treg-mediated protection of HSCs (51).
Donor Tregs seem as well to exert an engraftment facilitating 
effect without causing GvHD. In a fully MHC-mismatched BMT 
murine model, the co-transplantation of donor Tregs into suble-
thally conditioned recipients resulted in decreased early rejection 
of hematopoietic progenitors and improved long-term donor chi-
merism without inducing GvHD (52). The precise mechanisms 
through which host and donor Tregs exert their function on 
hematopoiesis are still incompletely understood. Transforming 
growth factor-β (TGF-β), a key mediator of Treg function, 
seems to play a role in Treg-mediated inhibition of IL-3-induced 
colony-forming units (46). Similarly, TGF-β is also involved in 
Treg engraftment facilitation as anti-TGF-β mAb treatment prior 
to allo-HSCT led to a significant increase in NK cell-mediated 
graft rejection, suggesting that Tregs mediate NK cell suppression 
through TGF-β (47). A major limitation of Treg-based therapies 
comes from the difficulties to isolate them from peripheral blood 
in sufficient amounts for adoptive transfer. Use of freshly isolated 
or ex vivo expanded third-party Tregs (53) or pharmacological 
approaches to induce Treg expansion in vivo represent potential 
alternatives. Administration of IL-2/anti-IL-2 mAb complexes 
to RIC conditioned mice early after MHC-matched allogeneic 
HSCT induces a strong expansion of host Tregs that efficiently 
facilitate early and long-term engraftment (54). Of note, in the 
absence of prior cytoreductive treatment, IL-2/anti-IL-2 com-
plexes administration failed to promote BM engraftment as its 
effect was extended to several lymphocytes populations (55). In 
addition to IL-2, other molecules inducing in  vivo expansion 
of Tregs display a potential to improve engraftment, including 
keratinocyte growth factor (KGF). KGF facilitated engraftment 
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in an MHC-matched HSCT murine model by increasing the 
frequency of Tregs and enhancing their in  vivo immunosup-
pression ability (56). Importantly KGF lost its ability to improve 
engraftment in Scurfy mice that lack Tregs.
Mesenchymal stem cells (MSCs) are stromal-derived multi-
potent progenitors displaying immune-modulatory properties 
of potential interest in HSCT [recently reviewed in Ref. (57)]. 
Several pilot studies performed in humans reported accelerated 
hematopoietic engraftment when MSCs were co-transplanted 
with HSC (58, 59), suggesting a potential for MSCs in preventing 
(58–61) and treating (58) GF.
iMMUnOLOGiCAL BASiS OF POOR 
GRAFT FUnCTiOn
While GF/rejection derives from “classical” alloreactive immune 
responses, PGF is the consequence of more complex and less well-
defined interactions between the immune system and the hemat-
opoietic compartment (Figure 1B). Important insights into the 
alloreactive immune responses involved in BMF syndromes first 
came from murine models of GvHD or aplastic anemia. Parental 
lymph node (LN) cells infusion into hybrid F1 with MHC-
mismatch either sublethally irradiated (62) or not (63) induced 
a drastic and cell dose-dependent reduction of hematopoietic 
progenitors and stem cells. Marrow aplasia was associated with 
massive infiltration by T cells, mainly of the CD8+ compartment 
(62). The observation of strongly increased interferon-γ (IFN-γ) 
concentrations in these models (62, 63) pointed to IFN-γ 
produced by alloreactive T cells as the main effector molecule 
mediating BMF in this setting. Similar results were reported in 
a MHC class II-disparate, CD4-dependent model of GvHD in 
which BM aplasia was associated with massive infiltration by 
CD4+ T cells secreting IFN-γ (64). Interestingly, IFN-γ produc-
ing CD4+ T cells in this model expressed high levels of CXCR4 
at their surface, suggesting a preferential BM homing potential. 
The relevance of IFN-γ as a key mediator of PGF in humans is 
supported by the observation of higher proportions of IFN-γ 
producing CD4+ and CD8+ T cells and decreased proportions of 
IL-4-producing T cells in BM from PGF patients, resulting in a 
shift of the IFN-γ/IL-4 ratio toward a type-1 immune response 
(65). IFN-γ and IL-4 levels in BM plasma were consistent with 
cellular results. The formal demonstration of the impact of IFN-γ 
in alloreactive PGF came from the observation that CD4+ T cells 
isolated from IFN-γKO mice adoptively co-transferred along 
with T-cell-depleted BM cells into sublethally irradiated recipi-
ents failed to induce the BM aplasia observed when WT CD4+ 
T cells were employed (66). Conversely, administration of IFN-γ 
receptor-1 deficient (IFN-γ-RKO) BM cells resulted in reduced 
severity of BMF (64). The use of IFN-γ-RKO recipients, in which 
extremely high, supraphysiological concentrations of IFN-γ are 
reached as a consequence of accumulation of IFN-γ produced by 
alloreactive T cells (67) or after inflammatory stimulation (68), 
provides complimentary information. In the MHC-matched, 
mHAg-mismatched C3H.SW > C57BL/6 transplantation model, 
donor HSCs were exposed to high levels of IFN-γ produced by 
alloreactive T cells leading to their decreased proliferation and 
finally to BM aplasia (67). A similar inhibition of HSCs was 
reported even when donor HSCs were transferred into syngenic 
IFN-γ-RKO mice in which extremely high levels of IFN-γ were 
induced through Mycobacterium bovis bacillus Calmette–Guérin 
(BCG) infection (68). Interestingly, the inhibitory effect of IFN-γ 
on hematopoiesis finally leads to lack of HSC engraftment despite 
the absence of alloreactive responses given the syngenic setting. 
Accordingly, using the already discussed BMF model induced by 
MHC-mismatch LN cells infusion, Chen and coworkers showed 
that co-transplantation of BM cells from BMF mice and from 
syngeneic healthy mice led to the destruction of hematopoietic 
progenitor stem and stromal cells from fully compatible healthy 
donors as “innocent bystanders” and not as targets (62). These 
observations suggest that, once elevated levels of IFN-γ are 
established, a non-HLA restricted inhibitory action is exerted 
on HSCs.
IFN-γ is a well-known negative regulator of HSC as demon-
strated since earliest in vitro studies in both murine (69, 70) and 
human (71, 72) cells. IFN-γ seems to facilitate HSC programmed 
cell death either directly (73) or through induction of caspase-1, 
TRAIL (74), and FAS (75). Moreover, IFN-γ inhibits HSC self-
renewal modulating expression of key cell-cycle genes, such 
as cyclin D1 (67, 76), Myc (67), and p57 (76). Notably, IFN-γ-
mediated cyclin D1 suppression seems to essentially affect the 
immature LSK (Lin−Sca-1+c-kit+) hematopoietic stem/progenitor 
cell (HSPC) subset but not mature Lin+ cells (67). Finally, IFN-γ 
interferes with thrombopoietin-induced phosphorylation of sig-
nal transducer and activator of transcription-5 (STAT-5) in HSCs 
through modulation of suppressor of cytokine signaling (SOCS) 
1 (76), further participating to inhibition of HSC proliferation 
through repression of STAT-5 target genes.
Collectively, these results suggest that in situations of chronic 
inflammation post allo-HSCT, such as GvHD or viral infections, 
PGF is, at least partially, the result of a sustained impairment 
of HSC self-renewal and proliferation caused by chronic IFN-γ 
exposure. In mice, IFN-γ blockade by administration of anti-
IFN-γ neutralizing antibodies significantly improved cytopenias 
reversing or preventing BM aplasia in all aforementioned BMF 
models in which this strategy was tested (62, 63, 67, 68). IFN-γ, 
therefore, probably represents the most promising target for 
immunotherapeutic interventions in PGF. Targeted treatment 
with anti-IFN-γ blocking antibodies (NI-0501) is currently under 
clinical evaluation in primary hemophagocytic lymphohistio-
cytosis (NCT01818492), another setting of immune-mediated 
BMF.
Tumor necrosis factor-α (TNF-α) represents another inflam-
matory cytokine that, if overexpressed, may participate in post-
allo-HSCT PGF mediation. Accumulating evidence has been 
established regarding the inhibitory role of TNF-α in clonogenic 
progenitor cells proliferation in vitro (77, 78). Incubation of LSK 
murine HSPC with TNF-α has been shown to upregulate Fas 
expression and to inhibit colony formation in vitro by reducing 
the size – but not the number – of proliferative clones (79), sug-
gesting that HSCs can undergo a limited number of cell divisions 
before becoming sensitive to TNF-induced growth inhibition. 
Transplantation of these cells into lethally irradiated mice resulted 
in reduced short-term engraftment and long-term reconstituting 
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activity, showing the impact of TNF-α on HSC function (79). 
Similarly, in a xenograft model of human CD34+CD38− cells 
treated with TNF-α in vitro and transplanted into NOD–SCID 
mice, their repopulating ability was dramatically compromised. 
A negative effect of TNF-α on HSC maintenance by enhancing 
their differentiation rather than self-renewal has been suggested 
(80). However, there is no general agreement about the in vivo 
role of TNF-α in HSC regulation. In BMF murine models, 
treatment with anti-TNF-α mAbs resulted in significantly 
prolongation of animal survival although less impressive than 
using anti-IFN-γ mAbs treatment (63). Furthermore, using mice 
deficient for either Tnfrsf1a receptor or Tnfrf1b receptor or both, 
a TNF-mediated suppression of HSCs activity was shown (81). 
Of note, it was dependent on both receptors as Tnfrsf1aKO and 
Tnfrsf1bKO BM cells presented a greater ability to long-term 
reconstitute myeloid and lymphoid cell lineages in myeloablated 
WT recipients compared to WT BM cells. This advantage was 
more pronounced when Tnfrsf1-doubleKO BM cells were used 
(81). It was also shown that in  vivo administration of TNF 
targets actively cycling rather than quiescent HSCs, finding of 
relevance in the early post-allo-HSCT setting where HSCs are 
recruited from quiescence to active proliferation. Conversely, a 
positive role of TNF-α in HSC engraftment and function has been 
reported in models of purified HSC transplantation into alloge-
neic and syngeneic mice in which small numbers of BM-derived 
CD8+/TCR− cells have been shown to act as graft facilitating cells 
through a TNF-α-dependent mechanism (82).
In addition to soluble inflammatory mediators, substantial 
evidence implicates the Fas/Fas ligand pathway in the post-allo-
HSCT PGF and mainly in the myelosuppressive effect of GvHD. 
Fas is expressed at CD34+ HSC surface (75, 83) and its expression 
is modulated by several factors, including IFN-γ and TNF-α (75). 
HSC exposure to agonist anti-Fas antibodies inhibits hematopoie-
sis by inducing HSC apoptosis (75, 83) and enhancing the effects 
of IFN-γ and TNF-α (75). In vivo, the Fas/FasL pathway has been 
shown to be relevant for BMF associated with cytomegalovirus 
infection (84) and GvHD (62, 63, 67, 83). In GvHD models, the 
use of FasL-defective (gld) donor cells prevented BM aplasia (83). 
Similarly, blockade of Fas/FasL interaction by the use of anti-FasL 
blocking antibodies significantly reduced cytopenias and BM 
aplasia (67, 83).
Hematopoiesis depends on special BM microenvironments 
known as “niches” in which HSCs reside as well as on the 
functional cross-talk between HSCs and these niches (85). 
BM endosteal, perivascular and vascular endothelial cells as 
well as osteoblasts have a fundamental role in the maintenance 
of HSCs by providing signals that regulate cell self-renewal, 
differentiation, and quiescence in mice (86). Two prospective 
nested case-control studies provided evidence that endosteal, 
perivascular cells, and endothelial progenitor cells are dra-
matically reduced in patients with primary and secondary PGF, 
suggesting that an impaired BM microenvironment hampers 
hematopoietic recovery after allo-HSCT (87, 88). The etiology 
of BM microenvironment impairment and how this leads to 
PGF remain unclear. Studies of BM GvHD in murine models 
identified osteoblasts as a major target for GvHD. Donor effec-
tor CD4+, and to a lesser extent CD8+, T cells caused early 
destruction of osteoblasts leading to severe impairment of B 
lymphopoiesis with dramatically decreased numbers of B-cell 
precursors and decreased expression of transcriptional factors 
essential for B lymphopoiesis, such as E2A and PAX5 (11). 
Surprisingly enough, there were no differences in serum levels 
of major inflammatory cytokines thought to be involved in 
GvHD, such as IL-1, IFN-γ, and TNF-α, suggesting that they 
are dispensable for CD4+ T cell-mediated osteoblast destruc-
tion. These findings were recently confirmed in allo-HSCT 
patients with PGF associated with chronic GvHD in which loss 
of osteoblasts, decreased numbers of B cells and an increased 
CD4/CD8 ratio were shown (89).
COnCLUSiOn
Bone marrow failure syndromes, namely GF and PGF, can 
develop after allo-HSCT and are associated with significant mor-
bidity and mortality. In the present paper, we summarized the 
distinct immune-pathological mechanisms underlying GF and 
PGF and we discussed evidence identifying several inflamma-
tory molecules as crucial mediators in their pathogenesis. Some 
preclinical evidence obtained in murine studies suggest that 
therapeutic interventions blocking these inflammatory mediators 
may represent a promising strategy to prevent and even reverse 
these severe complications.
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